Defiance Autism Impact ETF (ASD)

The Defiance Autism Impact ETF tracks companies working in autism diagnostics, pharmaceutical research, educational technology for neurodivergent learners, and employment support, backed by a commitment to donate advisory profits to autism-focused nonprofits.

What index does ASD follow?

The fund tracks the VettaFi Autism Impact Index, a curated portfolio of publicly traded companies whose products or services directly serve the autism ecosystem. The index screens for three broad categories: pharmaceutical and biotech firms advancing autism treatment and diagnostics, artificial-intelligence and software companies developing monitoring and assessment tools, and education-technology firms building inclusive learning systems. Rather than using a mechanical weighting formula, the index applies fundamental selection criteria, meaning companies rise and fall based on their actual involvement in the space, not merely on market capitalization.

How does the profit-donation structure work?

This is the fund’s defining feature. Defiance ETFs, the sponsor, commits to donate all net advisory profits from ASD to autism-focused nonprofits and research institutions for the first two years following launch. After that, the commitment continues at a 50-percent minimum of all future advisory profits, in perpetuity. This is not a donor designation by fund investors; it is the sponsor’s revenue commitment. A fund that attracts billions in assets generates substantial advisory fees, and Defiance is legally binding itself to route a significant portion of that income to autism causes. The actual amounts donated each year appear in the fund’s annual reports, making the pledge auditable and transparent.

What are the costs and how does the fund trade?

The expense ratio is 0.79 percent annually. On a $25,000 position, that translates to roughly $198 per year. For comparison, a broad healthcare index fund charges 0.05–0.15 percent, while other thematic ETFs in similar niches typically run 0.50–1.00 percent. ASD trades on the NASDAQ exchange with moderate liquidity — not the tight spreads of mega-cap index funds, but reasonable enough for typical retail trades. The fund’s asset base determines liquidity depth; a smaller fund may see wider bid-ask spreads on large positions.

What risks should an investor watch?

Thematic concentration is the primary risk. The autism-focused company universe is finite and sector-specific, meaning regulatory changes, clinical trial failures, or shifts in educational policy can cause the entire portfolio to move in tandem. Unlike a broad healthcare index with thousands of names, there is no diversification cushion. The companies in the index tend toward smaller and mid-cap firms rather than mega-cap stalwarts, adding volatility. The index methodology itself — determining what counts as serving the autism ecosystem — may evolve, potentially triggering surprise additions or removals that alter the fund’s character. Finally, as a newer thematic product, the fund has limited track record and may attract or repel flows based on trend rather than fundamentals.

How should someone research this fund before investing?

Start with the fund’s prospectus and fact sheet from Defiance ETFs, which document the index methodology and current holdings. Cross-check the top 10–15 companies against publicly available information — do they actually work in autism diagnostics, treatment, education, or employment support? Understand whether the portfolio tilts toward larger, established pharma players or smaller innovators, as that shapes volatility and earnings stability. Review the annual reports to confirm the charitable donations actually occurred and to what organizations. Compare the fund’s one-, three-, and five-year returns (when available) to broad healthcare and biotech indices, remembering that thematic underperformance over a period is entirely normal. Finally, ask whether holding ASD as a satellite position makes sense alongside a core portfolio of diversified index funds, or whether the thematic bet is sufficiently important to warrant concentrated capital.